AstraZeneca will not run TV or print ads for its recently approved pediatric indication on Nexium. The firm told the Delaware News Journal it would instead partner with patient advocacy groups to inform doctors that the drug is now approved as an acid reflux treatment for children ages 12–17.
From the June 01, 2006 Issue of MM+M - Medical Marketing and Media